TeselaGen and NinthBio Partner to Empower Users with Advanced DNA Variant Library Construction; Announcing Homology Path Design

The cutting-edge software integration enables researchers to design oligo assembly reactions, automate the reaction setup, order the needed DNA, and integrate with lab automation, all within a single platform

TeselaGen Biotechnology Inc., pioneer in AI-enabled Operating Systems for Biotechnology R&D and Manufacturing announces a strategic partnership with NinthBio LLC, the visionary Smart DNA Assembly Technology company. In a technical milestone, NinthBio’s cutting-edge Homology Path design algorithm now integrates with TeselaGen’s powerful software platform. This integration empowers researchers to accelerate their research by seamlessly enabling users to design and build DNA constructs more efficiently, saving valuable time and resources, all through a single platform.

By combining NinthBio’s Homology Path algorithm with TeselaGen’s comprehensive suite of tools, users can rapidly construct DNA variant libraries at a high throughput. The integration allows R&D teams in biotechnology to accelerate scientific discoveries and streamline their DNA assembly processes via advanced design algorithms to unlock new biotech applications enabled by protein engineering.

“By partnering with NinthBio, we empower researchers, innovators, and visionaries to unlock the full potential of biotechnology, speeding unprecedented advancements and shaping a future of limitless possibilities.”, said Eduardo Abeliuk, Ph.D., CEO of TeselaGen.

In the past, research groups outsourced the generation of their variant libraries because they lacked an efficient way to build them in-house. Now, users can seamlessly access Homology Path to quickly design oligo assembly reactions. Likewise, researchers who currently use Homology Path can lean on TeselaGen’s software to execute these reactions, including inventory management, oligo ordering, sample tracking and automated generation of worklists for liquid handling robots.

“By integrating NinthBio’s groundbreaking Homology Path design algorithm with TeselaGen’s innovative software platform, we are revolutionizing the way researchers approach DNA variant library construction,” states Steve Riedmuller, CEO of NinthBio. ”

This collaboration represents a significant step forward in advancing the field of biotechnology and reinforces both TeselaGen and NinthBio’s commitment to empowering scientists and innovators with cutting-edge tools and technologies.

“This joint effort aims to revolutionize the way DNA libraries are constructed and expedite breakthroughs in fields such as drug discovery, sustainable agriculture, and industrial biotechnology,” continues Abeliuk.

NinthBio and Teselagen will showcase their new integration at the SynBioBeta Conference, May 23-25 in Oakland, California. Conference attendees can view a demonstration of the integration and meet the team at Booth #58.

For more information about this integration or to learn more about how to build variant libraries faster and cheaper than outsourcing them, check out www.teselagen.com/integrations

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.